Related Experiment Video
Updated: Jun 27, 2026
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
PARK2-Mediated PGK1 Degradation Suppresses Partial Epithelial-Mesenchymal Transition and Metastasis in
Zhengzheng Li1,2, Haitong Xie1,2, Yujuan Chen1,2
1Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
Abstract:
Objectives: Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies. Phosphoglycerate kinase 1 (PGK1) drives TNBC progression, but mechanisms governing its protein stability remain unclear. This study aims to identify the E3 ubiquitin ligase responsible for PGK1 degradation and evaluate its therapeutic potential against metastasis. Methods: Clinical datasets and 50 human TNBC tissues were analyzed via multiplex immunohistochemistry. Co-immunoprecipitation, ubiquitination linkage assays, and structural modeling were utilized for in vitro mechanistic studies in TNBC cells. Additionally, functional impacts on epithelial-mesenchymal transition (EMT) and metastasis were evaluated using transwell assays and an in vivo mouse lung metastasis model. Results: Parkinson disease protein 2 (PARK2) is a novel E3 ubiquitin ligase that mediates proteasomal degradation of PGK1 in TNBC cells. Elevated PGK1 expression and reduced PARK2 expression in TNBC, with high PGK1 levels correlating with unfavorable overall survival (HR: 2.138, 95%CI:1.001 to 4.569, p = 0.049). PARK2 physically binds PGK1 via its RING2 domain and promotes K48-linked polyubiquitination, leading to proteasomal degradation. A significant negative correlation between PARK2 and PGK1 at the protein levels were confirmed in 50 TNBC tumor tissues (Spearman's rho = -0.58, p < 0.001). Functionally, PARK2 overexpression reduced mesenchymal markers (Vimentin, Snail1, Slug) and suppressed migration and invasion of TNBC cells, effects that were reversed by PGK1 overexpression. PARK2 significantly inhibited PGK1-mediated lung metastasis in in vivo tail vein injection models Conclusion: These findings establish the PARK2-PGK1 axis as a critical regulator of partial epithelial-mesenchymal transition and metastasis in TNBC, suggesting that strategies to enhance PARK2 expression or activity may represent promising therapeutic approaches for this aggressive breast cancer subtype.
Insights
Parkinson disease protein 2 (PARK2) targets phosphoglycerate kinase 1 (PGK1) for degradation in triple-negative breast cancer (TNBC). Enhancing PARK2 may offer new therapeutic strategies against TNBC metastasis.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Triple-negative breast cancer (TNBC) is aggressive and lacks targeted therapies.
- Phosphoglycerate kinase 1 (PGK1) promotes TNBC progression, but its stability regulation is unknown.
- Understanding PGK1 regulation is crucial for developing new TNBC treatments.
Purpose of the Study:
- Identify the E3 ubiquitin ligase targeting PGK1 for degradation.
- Investigate the role of this ligase in TNBC progression and metastasis.
- Evaluate its therapeutic potential against TNBC metastasis.
Main Methods:
- Analysis of clinical TNBC datasets and patient tissues.
- In vitro studies using co-immunoprecipitation and ubiquitination assays.
- In vivo metastasis models in mice and functional assays for cell migration.
Main Results:
- Parkinson disease protein 2 (PARK2) was identified as the E3 ubiquitin ligase for PGK1.
- PARK2 binds PGK1, promoting its K48-linked polyubiquitination and proteasomal degradation.
- Elevated PGK1 and reduced PARK2 correlate with poor survival in TNBC patients.
- PARK2 overexpression suppressed TNBC cell migration, invasion, and lung metastasis.
Conclusions:
- The PARK2-PGK1 axis is a key regulator of epithelial-mesenchymal transition and metastasis in TNBC.
- PARK2 acts as a tumor suppressor by degrading PGK1.
- Enhancing PARK2 activity presents a potential therapeutic strategy for TNBC.
Related Concept Videos
02:23Abnormal Proliferation
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:38Mitogens and the Cell Cycle